BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Acorda Therapeutics 

15 Skyline Drive

Hawthorne  New York  10532  U.S.A.
Phone: 914-347-4300 Fax: 914-347-4560


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Acorda Therapeutics is a privately held biotechnology company developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS.

Fampridine-SR acts to combat the effects of demyelination in the spinal cord. Myelin is the insulating sheath around nerve processes; when it is damaged due to trauma or disease, electrical impulses from the brain cannot be conducted past the demyelinated area. Fampridine-SR chemically blocks the exposed voltage-gated potassium channels, allowing the impulse from the brain to be conducted more normally past the area of damage. Fampridine is being studied in Phase 3 clinical trials to evaluate its efficacy in reducing spasticity in people with chronic spinal cord injury. Secondary endpoints in the study include evaluating its effect on bladder, bowel, and sexual function. The Company is also conducting a 152 patient, late Phase 2 clinical study in MS to evaluate Fampridine-SR's efficacy in walking speed and muscle strength.

Acorda's technology platform also includes two remyelinating agents in preclinical development for MS. The first is M1, a class of human monoclonal antibodies that have been shown to remyelinate the central nervous system in animal models, and the second is GGF2, a product of the neuregulin 1 gene. Preclinical studies have shown that GGF2 can stimulate the cell growth necessary to protect and regenerate damaged myelin. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain.

In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.

Key Management:

Ron Cohen, M.D., President and CEO
Andrew R. Blight, Ph.D., Executive Vice President, Research & Development
Mary Fisher, Vice President, Marketing and Strategic Planning
Elliott A. Gruskin, Ph.D., Vice President, Research & Development
Mitchell Katz, Ph.D., Vice President, Clinical Programs
David Lawrence, Vice President, Finance
Mark R. E. Pinney, C.F.A., Chief Financial Officer and Director
Harold Safferstein, Ph.D., J.D., Vice President, Business Development

Last Updated: 05-09-03


 Key Statistics


Email: acorda@acorda.com
Ownership:

Web Site: Acorda Therapeutics
Employees:
Symbol: ACOR
 



Industry
Biotechnology

Segment
Pharmaceuticals

Collaborations

Athersys, Inc.  A functional genomics collaboration focused on the discovery of validated drug targets to treat certain central nervous system disorders, including spinal cord injuries and multiple sclerosis. Athersys and Acorda will jointly own therapeutic products or validated targets identified and developed through the collaboration.

Alkermes plc 





 Company News
Acorda Therapeutics (ACOR) And HealthCore To Present Real World Health Economics And Outcomes Data On Multiple Sclerosis Therapy AMPYRA 9/10/2014 11:15:11 AM
Acorda Therapeutics (ACOR) To Present At The Aegis Capital 2014 Healthcare And Technology Conference 9/4/2014 12:21:55 PM
Acorda Therapeutics (ACOR) To Present At The Morgan Stanley (MST) Global Healthcare Conference 9/2/2014 1:45:05 PM
Acorda Therapeutics (ACOR) To Present At The Baird 2014 Healthcare Conference 8/27/2014 8:56:11 AM
Acorda Therapeutics (ACOR) To Host Conference Call To Discuss Second Quarter 2014 Financial Results On July 31, 2014 7/24/2014 11:20:34 AM
Acorda Therapeutics (ACOR)' Multiple Sclerosis Drug AMPYRA® Faces Generic Threat 6/26/2014 6:15:23 AM
Acorda Therapeutics (ACOR) Announces Pricing of $300 Million Of 1.75% Convertible Senior Notes Due 2021 6/18/2014 7:02:54 AM
Acorda Therapeutics (ACOR) Announces Public Offering Of Convertible Senior Notes Due 2021 6/17/2014 12:53:45 PM
Acorda Therapeutics (ACOR) To Present At The Jefferies and Co. 2014 Global Healthcare Conference 5/28/2014 7:29:12 AM
Acorda Therapeutics (ACOR) To Showcase Online Multiple Sclerosis Resources At 2014 CMSC/ACTRIMS Meeting 5/27/2014 6:49:49 AM
12345678910...